{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:27:29Z","timestamp":1793946449448,"version":"4.8.0"},"reference-count":129,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.critrevonc.2026.105427","type":"journal-article","created":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T15:35:15Z","timestamp":1780760115000},"page":"105427","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["The evolving landscape of CDK2 inhibition in cancer: Therapeutic potential, clinical progress, and future directions"],"prefix":"10.1016","volume":"226","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9645-2797","authenticated-orcid":false,"given":"Jimma Likisa","family":"Lenjisa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Kasirzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ava","family":"Safaroghli-azar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laychiluh Bantie","family":"Mekonnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.critrevonc.2026.105427_bib1","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/nrd3186","article-title":"Trgeted cancer therapies","volume":"9","author":"Aggarwal","year":"2010","journal-title":"Nat. Rev. Drug. Discov."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105427_bib2","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1158\/0008-5472.CAN-10-4086","article-title":"Cdk2 is required for breast cancer mediated by the low-molecular-weight isoform of cyclin E","volume":"71","author":"Akli","year":"2011","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105427_bib3","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41698-022-00311-6","article-title":"Co-targeting CDK2 and CDK4\/6 overcomes resistance to aromatase and CDK4\/6 inhibitors in ER+ breast cancer","volume":"6","author":"Al-Qasem","year":"2022","journal-title":"NPJ Precis. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105427_bib4","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1016\/j.cell.2023.05.013","article-title":"Rapid adaptation to CDK2 inhibition exposes intrinsic cell-cycle plasticity","volume":"186","author":"Arora","year":"2023","journal-title":"Cell"},{"issue":"1_","key":"10.1016\/j.critrevonc.2026.105427_bib5","doi-asserted-by":"crossref","first-page":"i17","DOI":"10.1093\/annonc\/mdx145","article-title":"Unravelling mechanisms of resistance to CDK4\/6 inhibitors using triple negative breast cancer (TNBC)","volume":"28","author":"Asghar","year":"2017","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105427_bib6","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/nrd4504","article-title":"The history and future of targeting cyclin-dependent kinases in cancer therapy","volume":"14","author":"Asghar","year":"2015","journal-title":"Nat. Rev. Drug. Discov."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105427_bib7","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/nrd4504","article-title":"The history and future of targeting cyclin-dependent kinases in cancer therapy","volume":"14","author":"Asghar","year":"2015","journal-title":"Nat. Rev. Drug. Discov."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105427_bib8","doi-asserted-by":"crossref","DOI":"10.15252\/msb.20177858","article-title":"Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors","volume":"14","author":"Azimi","year":"2018","journal-title":"Mol. Syst. Biol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105427_bib9","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ygyno.2018.08.039","article-title":"19q12 amplified and non-amplified subsets of high grade serous ovarian cancer with overexpression of cyclin E1 differ in their molecular drivers and clinical outcomes","volume":"151","author":"Aziz","year":"2018","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105427_bib10","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/s41523-021-00312-x","article-title":"Synergistic targeting of BRCA1 mutated breast cancers with PARP and CDK2 inhibition","volume":"7","author":"Aziz","year":"2021","journal-title":"npj Breast Cancer"},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105427_bib11","doi-asserted-by":"crossref","first-page":"5085","DOI":"10.1158\/0008-5472.CAN-09-4095","article-title":"Cyclin E deregulation impairs mitotic progression through premature activation of Cdc25C","volume":"70","author":"Bagheri-Yarmand","year":"2010","journal-title":"Cancer Res."},{"issue":"12_ement","key":"10.1016\/j.critrevonc.2026.105427_bib12","article-title":"Abstract P4-12-29: ETX-197\/BG-68501, a potential best-in-class potent, selective, oral, small molecule CDK2 inhibitor, has anti-tumor activity in cancer models with Cyclin E amplification or deficiency in the Retinoblastoma 1 gene","volume":"31","author":"Banerjee","year":"2025","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105427_bib13","doi-asserted-by":"crossref","first-page":"5235","DOI":"10.1038\/s41467-018-07552-9","article-title":"Cyclin A2\/E1 activation defines a hepatocellular carcinoma subclass with a rearrangement signature of replication stress","volume":"9","author":"Bayard","year":"2018","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105427_bib14","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/15384101.2020.1855740","article-title":"Pharmacological inactivation of CDK2 inhibits MYC\/BCL-XL-driven leukemia in vivo through induction of cellular senescence","volume":"20","author":"Bazzar","year":"2021","journal-title":"Cell. Cycle"},{"issue":"20","key":"10.1016\/j.critrevonc.2026.105427_bib15","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1016\/j.cub.2003.09.024","article-title":"Cdk2 knockout mice are viable","volume":"13","author":"Berthet","year":"2003","journal-title":"Curr. Biol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105427_bib16","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s41571-019-0170-z","article-title":"Approvals in 2018: a histology-agnostic new molecular entity, novel end points and real-time review","volume":"16","author":"Blumenthal","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105427_bib17","first-page":"15","article-title":"Anthracycline-induced cardiotoxicity in the chemotherapy treatment of breast cancer: preventive strategies and treatment","volume":"11","author":"Cai","year":"2019","journal-title":"Mol. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105427_bib18","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/ncb2004","article-title":"Cdk2 suppresses cellular senescence induced by the c-myc oncogene","volume":"12","author":"Campaner","year":"2009","journal-title":"Nat. Cell. Biol."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105427_bib19","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1093\/cvr\/cvae084","article-title":"Inhibition of cyclin-dependent kinase 7 mitigates doxorubicin cardiotoxicity and enhances anticancer efficacy","volume":"120","author":"Chen","year":"2024","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.critrevonc.2026.105427_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117503","article-title":"Discovery of potent and selective CDK2 inhibitors with high safety and favorable bioavailability for the treatment of cancer","volume":"290","author":"Chen","year":"2025","journal-title":"Eur. J. Med. Chem."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105427_bib21","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1158\/2326-6066.CIR-21-0806","article-title":"CDK2 Inhibition Enhances Antitumor Immunity by Increasing IFN Response to Endogenous Retroviruses","volume":"10","author":"Chen","year":"2022","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.critrevonc.2026.105427_bib22","first-page":"2025","article-title":"CDK2 inhibition sensitizes anthracycline-induced immunogenic cell death and enhances the efficacy of anti-PD-1 therapy","volume":"16","author":"Chen","year":"2025","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105427_bib23","doi-asserted-by":"crossref","first-page":"237","DOI":"10.2174\/0929867321666141106113633","article-title":"Cyclin-dependent kinase-2 as a target for cancer therapy: progress in the development of CDK2 inhibitors as anti-cancer agents","volume":"22","author":"Chohan","year":"2015","journal-title":"Curr. Med. Chem."},{"issue":"13_ement","key":"10.1016\/j.critrevonc.2026.105427_bib24","article-title":"Abstract 1279: development of a selective CDK2-E inhibitor in CCNE driven cancers","volume":"81","author":"Choi","year":"2021","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105427_bib25","doi-asserted-by":"crossref","first-page":"5659","DOI":"10.4049\/jimmunol.1202313","article-title":"Cyclin-dependent kinase 2 controls peripheral immune tolerance","volume":"189","author":"Chunder","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105427_bib26","article-title":"MYC Serine 62 phosphorylation promotes its binding to DNA double strand breaks to facilitate repair and cell survival under genotoxic stress","volume":"2025","author":"Cohn","year":"2025","journal-title":"bioRxiv"},{"issue":"16_suppl","key":"10.1016\/j.critrevonc.2026.105427_bib27","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.5514","article-title":"Safety and preliminary efficacy from a phase 1 study of INCB123667, a selective CDK2 inhibitor, in patients with advanced platinum-resistant and refractory ovarian cancer (OC)","volume":"43","author":"Damian","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"16","key":"10.1016\/j.critrevonc.2026.105427_bib28","doi-asserted-by":"crossref","first-page":"8219","DOI":"10.1158\/0008-5472.CAN-05-3945","article-title":"Cyclin-dependent kinase 2 functions in normal DNA repair and is a therapeutic target in BRCA1-deficient cancers","volume":"66","author":"Deans","year":"2006","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105427_bib29","first-page":"72","article-title":"Chromosomal mapping of human CDK2, CDK4, and CDK5 cell cycle kinase genes","volume":"66","author":"Demetrick","year":"1994","journal-title":"Cytogenet. Genome Res."},{"issue":"7_ement","key":"10.1016\/j.critrevonc.2026.105427_bib30","article-title":"Abstract ND06: First disclosure of AZD8421, a highly selective CDK2 inhibitor to address resistance to CDK4\/6 inhibitors in breast and CCNE1-high cancers","volume":"84","author":"Denz","year":"2024","journal-title":"Cancer Res."},{"issue":"30","key":"10.1016\/j.critrevonc.2026.105427_bib31","doi-asserted-by":"crossref","first-page":"4626","DOI":"10.1038\/sj.onc.1205576","article-title":"Ectopic expression of cyclin E in estrogen responsive cells abrogates antiestrogen mediated growth arrest","volume":"21","author":"Dhillon","year":"2002","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105427_bib32","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1158\/2159-8290.CD-23-0954","article-title":"INX-315, a selective CDK2 inhibitor, induces cell cycle arrest and senescence in solid tumors","volume":"14","author":"Dietrich","year":"2024","journal-title":"Cancer Discov."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105427_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1002538","article-title":"LMW-E\/CDK2 deregulates acinar morphogenesis, induces tumorigenesis, and associates with the activated b-Raf-ERK1\/2-mTOR pathway in breast cancer patients","volume":"8","author":"Duong","year":"2012","journal-title":"PLoS. Genet."},{"key":"10.1016\/j.critrevonc.2026.105427_bib34","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s002800050832","article-title":"Drug resistance to 5-aza-2\u2032-deoxycytidine, 2\u2032, 2\u2032-difluorodeoxycytidine, and cytosine arabinoside conferred by retroviral-mediated transfer of human cytidine deaminase cDNA into murine cells","volume":"42","author":"Eliopoulos","year":"1998","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.critrevonc.2026.105427_bib35","first-page":"9","article-title":"Cyclin E\/CDK2: DNA replication, replication stress and genomic instability","author":"Fagundes","year":"2021","journal-title":"Front. Cell. Dev. Biol."},{"issue":"14","key":"10.1016\/j.critrevonc.2026.105427_bib36","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkaf706","article-title":"The function of MYC in base excision repair protects against RAS-induced senescence","volume":"53","author":"Faraco","year":"2025","journal-title":"Nucleic Acids Res."},{"issue":"6577","key":"10.1016\/j.critrevonc.2026.105427_bib37","doi-asserted-by":"crossref","first-page":"eabc1495","DOI":"10.1126\/science.abc1495","article-title":"CDK4 and CDK6 kinases: from basic science to cancer therapy","volume":"375","author":"Fassl","year":"2022","journal-title":"Science"},{"issue":"17","key":"10.1016\/j.critrevonc.2026.105427_bib38","doi-asserted-by":"crossref","first-page":"5748","DOI":"10.1002\/cam4.4089","article-title":"Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy-induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trials","volume":"10","author":"Ferrarotto","year":"2021","journal-title":"Cancer Med."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105427_bib39","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.ccell.2021.08.009","article-title":"Expanding control of the tumor cell cycle with a CDK2\/4\/6 inhibitor","volume":"39","author":"Freeman-Cook","year":"2021","journal-title":"Cancer Cell."},{"issue":"6_ement","key":"10.1016\/j.critrevonc.2026.105427_bib40","article-title":"Abstract 5705: Discovery of a selective slow-off CDK2 inhibitor NKT3447 with distinct features of suppressing pCDK2, downregulating cyclin E, and achieving prolonged pathway inhibition","volume":"84","author":"Geng","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105427_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104324","article-title":"Cyclin-dependent kinase 2 (CDK2) inhibitors and others novel CDK inhibitors (CDKi) in breast cancer: clinical trials, current impact, and future directions","volume":"196","author":"Gerosa","year":"2024","journal-title":"Crit. Rev. Oncol. \/Hematol."},{"issue":"17","key":"10.1016\/j.critrevonc.2026.105427_bib42","doi-asserted-by":"crossref","first-page":"18164","DOI":"10.1021\/acs.jmedchem.5c01478","article-title":"Discovery of AZD8421: a potent CDK2 inhibitor with selectivity against other CDK family members and the human kinome","volume":"68","author":"Ghosh","year":"2025","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105427_bib43","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/s41568-022-00456-3","article-title":"Targeting CDK4 and CDK6 in cancer","volume":"22","author":"Goel","year":"2022","journal-title":"Nat. Rev. Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105427_bib44","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3390\/diagnostics10050279","article-title":"CCNE1 amplification as a predictive biomarker of chemotherapy resistance in epithelial ovarian cancer","volume":"10","author":"Gorski","year":"2020","journal-title":"Diagnostics"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105427_bib45","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0092-8674(00)80994-0","article-title":"Cdk2 kinase is required for entry into mitosis as a positive regulator of Cdc2\u2013Cyclin B kinase activity","volume":"84","author":"Guadagno","year":"1996","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105427_bib46","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41523-020-00181-w","article-title":"Cyclin E expression is associated with high levels of replication stress in triple-negative breast cancer","volume":"6","author":"Guerrero Llobet","year":"2020","journal-title":"npj Breast Cancer"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105427_bib47","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1158\/0008-5472.CAN-15-0728","article-title":"Early adaptation and acquired resistance to CDK4\/6 inhibition in estrogen receptor\u2013positive breast cancer","volume":"76","author":"Herrera-Abreu","year":"2016","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105427_bib48","doi-asserted-by":"crossref","first-page":"F112","DOI":"10.1152\/ajprenal.00151.2010","article-title":"Protection of cisplatin cytotoxicity by an inactive cyclin-dependent kinase","volume":"299","author":"Hodeify","year":"2010","journal-title":"Am. J. Physiol. Ren. Physiol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105427_bib49","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1152\/ajprenal.00507.2010","article-title":"Cdk2-dependent phosphorylation of p21 regulates the role of Cdk2 in cisplatin cytotoxicity","volume":"300","author":"Hodeify","year":"2011","journal-title":"Am. J. Physiol. Ren. Physiol."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105427_bib50","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1158\/0008-5472.CAN-24-2360","article-title":"Profiling the activity of the potent and highly selective CDK2 inhibitor BLU-222 reveals determinants of response in CCNE1-aberrant ovarian and endometrial tumors","volume":"85","author":"House","year":"2025","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105427_bib51","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41523-025-00851-7","article-title":"CDK2 inhibition enhances CDK4\/6 inhibitor antitumor activity in comprehensive breast cancer PDX model screen","volume":"11","author":"House","year":"2025","journal-title":"NPJ Breast Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105427_bib52","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.tips.2013.11.004","article-title":"Molecularly targeted cancer therapy: some lessons from the past decade","volume":"35","author":"Huang","year":"2025","journal-title":"Trends Pharmacol. Sci."},{"issue":"12_ement","key":"10.1016\/j.critrevonc.2026.105427_bib53","article-title":"Abstract P5-01-26: selective targeting of CDK2 using molecular glue degraders for the treatment of HR-positive\/HER2-negative breast cancer","volume":"31","author":"Ilic-Widlund","year":"2025","journal-title":"Clin. Cancer Res."},{"issue":"16_","key":"10.1016\/j.critrevonc.2026.105427_bib54","volume":"43","author":"Joshi","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"16_suppl","key":"10.1016\/j.critrevonc.2026.105427_bib55","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.1056","article-title":"BLU-222, an investigational, oral, potent, and highly selective CDK2 inhibitor (CDK2i), as monotherapy in patients (pts) with advanced solid tumors and in combination with ribociclib (RIBO) and fulvestrant (FUL) in HR+\/HER2\u2212 breast cancer (BC)","volume":"42","author":"Juric","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105427_bib56","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.4161\/cc.4.11.2124","article-title":"Cell cycle sibling rivalry: Cdc2 vs. Cdk2","volume":"4","author":"Kaldis","year":"2005","journal-title":"Cell. Cycle"},{"issue":"39","key":"10.1016\/j.critrevonc.2026.105427_bib57","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1080\/14796694.2024.2416382","article-title":"Targeting CDK2 to combat drug resistance in cancer therapy","volume":"20","author":"Kasirzadeh","year":"2024","journal-title":"Future Oncol."},{"issue":"14","key":"10.1016\/j.critrevonc.2026.105427_bib58","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1016\/j.devcel.2022.06.008","article-title":"A ROS-dependent mechanism promotes CDK2 phosphorylation to drive progression through S phase","volume":"57","author":"Kirova","year":"2022","journal-title":"Dev. Cell."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105427_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110448","article-title":"CDK\/cyclin dependencies define extreme cancer cell-cycle heterogeneity and collateral vulnerabilities","volume":"38","author":"Knudsen","year":"2022","journal-title":"Cell. Rep."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105427_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.116140","article-title":"Targeting CDK2 for cancer therapy","volume":"44","author":"Knudsen","year":"2025","journal-title":"Cell. Rep."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105427_bib61","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1056\/NEJMra044389","article-title":"Tyrosine kinases as targets for cancer therapy","volume":"353","author":"Krause","year":"2005","journal-title":"New. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105427_bib62","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1038\/s41467-025-56674-4","article-title":"Discrete vulnerability to pharmacological CDK2 inhibition is governed by heterogeneity of the cancer cell cycle","volume":"16","author":"Kumarasamy","year":"2025","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105427_bib63","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.chembiol.2025.03.006","article-title":"CDK2 heterobifunctional degraders co-degrade CDK2 and cyclin E resulting in efficacy in CCNE1-amplified and overexpressed cancers","volume":"32","author":"Kwiatkowski","year":"2025","journal-title":"Cell. Chem. Biol."},{"key":"10.1016\/j.critrevonc.2026.105427_bib64","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/nrc2827","article-title":"What are the hallmarks of cancer?","volume":"10","author":"Lazebnik","year":"2010","journal-title":"Nat. Rev. Cancer"},{"issue":"16","key":"10.1016\/j.critrevonc.2026.105427_bib65","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.4155\/fmc-2017-0097","article-title":"CDK5 in oncology: recent advances and future prospects","volume":"9","author":"Lenjisa","year":"2017","journal-title":"Future Med. Chem."},{"issue":"21","key":"10.1016\/j.critrevonc.2026.105427_bib66","article-title":"Inhibition Of Cdk2 promotes the generation of inducible CD8+ T regulatory cells by modulating the epigenetic regulator EZH2","volume":"122","author":"Li","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2026.105427_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2022.146325","article-title":"A comprehensive bioinformatic analysis of cyclin-dependent kinase 2 (CDK2) in glioma","volume":"822","author":"Liu","year":"2022","journal-title":"Gene"},{"key":"10.1016\/j.critrevonc.2026.105427_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.dnarep.2019.102702","article-title":"To control or to be controlled? Dual roles of CDK2 in DNA damage and DNA damage response","volume":"85","author":"Liu","year":"2020","journal-title":"DNA Repair."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105427_bib69","doi-asserted-by":"crossref","first-page":"5154","DOI":"10.1038\/s41467-025-60293-4","article-title":"Inhibition of tumor-intrinsic NAT10 enhances antitumor immunity by triggering type I interferon response via MYC\/CDK2\/DNMT1 pathway","volume":"16","author":"Liu","year":"2025","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105427_bib70","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/s41467-025-67865-4","article-title":"CDK2 inhibitor BLU-222 synergizes with CDK4\/6 inhibitors in drug resistant breast cancers through p21\/p27 induction","volume":"17","author":"Luo","year":"2026","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105427_bib71","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrc2602","article-title":"Cell cycle, CDKs and cancer: a changing paradigm","volume":"9","author":"Malumbres","year":"2009","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105427_bib72","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/s41698-025-00931-8","article-title":"Targeting CDKs in cancer therapy: advances in PROTACs and molecular glues","volume":"9","author":"Marei","year":"2025","journal-title":"npj Precis. Oncol."},{"issue":"8_ement_1","key":"10.1016\/j.critrevonc.2026.105427_bib73","article-title":"Abstract 6375: Discovery and characterization of novel, potent and selective CDK2 molecular glue degrader against CCNE1-amplified tumors","volume":"85","author":"Martin","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105427_bib74","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.canlet.2018.04.037","article-title":"Cyclin E overexpression confers resistance to the CDK4\/6 specific inhibitor palbociclib in gastric cancer cells","volume":"430","author":"Min","year":"2018","journal-title":"Cancer Lett."},{"issue":"29","key":"10.1016\/j.critrevonc.2026.105427_bib75","doi-asserted-by":"crossref","first-page":"11960","DOI":"10.1073\/pnas.0904875106","article-title":"A hyperfused mitochondrial state achieved at G1-S regulates cyclin E buildup and entry into S phase","volume":"106","author":"Mitra","year":"2009","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"34","key":"10.1016\/j.critrevonc.2026.105427_bib76","doi-asserted-by":"crossref","first-page":"24494","DOI":"10.1074\/jbc.M113.467704","article-title":"Foxp3 Protein Stability Is Regulated by Cyclin-dependent Kinase 2*","volume":"288","author":"Morawski","year":"2013","journal-title":"J. Biol. Chem."},{"issue":"7353","key":"10.1016\/j.critrevonc.2026.105427_bib77","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"The Cancer Genome Atlas Research Network","year":"2011","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105427_bib78","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/annonc\/mdh097","article-title":"Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX\u2122\/Doxil\u00ae) versus conventional doxorubicin for first-line treatment of metastatic breast cancer","volume":"15","author":"O\u2019Brien","year":"2004","journal-title":"Ann. Oncol."},{"issue":"20","key":"10.1016\/j.critrevonc.2026.105427_bib79","first-page":"3302","article-title":"Cyclin A\/Cdk2 regulates Cdh1 and claspin during late S\/G2 phase of the cell cycle. Cell cycle (Georgetown","volume":"13","author":"Oakes","year":"2014","journal-title":"Tex )"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105427_bib80","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.3892\/ijo.2014.2523","article-title":"Inhibition of Cdk2 kinase activity selectively targets the CD44\u207a\/CD24\u207b\/Low stem-like subpopulation and restores chemosensitivity of SUM149PT triple-negative breast cancer cells","volume":"45","author":"Opyrchal","year":"2014","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105427_bib81","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nrc.2016.138","article-title":"Cell cycle proteins as promising targets in cancer therapy","volume":"17","author":"Otto","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105427_bib82","doi-asserted-by":"crossref","unstructured":"Pandey, K., Park, N., Park, K.-S., Hur, J., Cho, Y.B., Kang, M., An, H.-J., Kim, S., Hwang, S., Moon, Y.W., 2020. Combined CDK2 and CDK4\/6 Inhibition Overcomes Palbociclib Resistance in Breast Cancer by Enhancing Senescence, Cancers (Basel).","DOI":"10.3390\/cancers12123566"},{"issue":"16_","key":"10.1016\/j.critrevonc.2026.105427_bib83","article-title":"BLU-222, an oral, potent, and selective CDK2 inhibitor, in patients with advanced solid tumors: Phase 1 monotherapy dose escalation","volume":"41","author":"Patel","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"5_ement","key":"10.1016\/j.critrevonc.2026.105427_bib84","article-title":"Abstract OT3-23-01: VELA: A first-in-human phase 1\/2 study of BLU-222, a potent, selective cyclin-dependent kinase (CDK) 2 inhibitor in patients with cyclin E1 gene (CCNE1)-amplified or CDK4\/6 inhibitor-resistant advanced solid tumors","volume":"83","author":"Patel","year":"2023","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105427_bib85","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.cmet.2022.01.007","article-title":"The hallmarks of cancer metabolism: Still emerging","volume":"34","author":"Pavlova","year":"2022","journal-title":"Cell. Metab."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105427_bib86","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3390\/cancers7010179","article-title":"Targeting cyclin-dependent kinases in human cancers: from small molecules to Peptide inhibitors","volume":"7","author":"Peyressatre","year":"2015","journal-title":"Cancers (Basel)"},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105427_bib87","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1681\/ASN.2006020162","article-title":"Dependence of cisplatin-induced cell death in vitro and in vivo on cyclin-dependent kinase 2","volume":"17","author":"Price","year":"2006","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.critrevonc.2026.105427_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107059","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: A 2024 update","volume":"200","author":"Roskoski","year":"2024","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.critrevonc.2026.105427_bib89","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.phrs.2019.03.006","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors","volume":"144","author":"Roskoski","year":"2019","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.critrevonc.2026.105427_bib90","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106552","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: A 2023 update","volume":"187","author":"Roskoski","year":"2023","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.critrevonc.2026.105427_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2025.107723","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: A 2025 update","volume":"216","author":"Roskoski","year":"2025","journal-title":"Pharmacol. Res."},{"issue":"37","key":"10.1016\/j.critrevonc.2026.105427_bib92","doi-asserted-by":"crossref","first-page":"62240","DOI":"10.18632\/oncotarget.19272","article-title":"CCNE1 expression in high grade serous carcinoma does not correlate with chemoresistance","volume":"8","author":"Sapoznik","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2026.105427_bib93","doi-asserted-by":"crossref","unstructured":"Scaltriti, M., Eichhorn, P.J., Cort\u00e9s, J., Prudkin, L., Aura, C., Jim\u00e9nez, J., Chandarlapaty, S., Serra, V., Prat, A., Ibrahim, Y.H., 2011. Cyclin E amplification\/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients. Proceedings of the National Academy of Sciences 108(9), 3761-3766.","DOI":"10.1073\/pnas.1014835108"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105427_bib94","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/s41571-022-00668-4","article-title":"Senescence and cancer \u2014 role and therapeutic opportunities","volume":"19","author":"Schmitt","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105427_bib95","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104545","article-title":"CDK2 suppression synergizes with all-trans-retinoic acid to overcome the myeloid differentiation blockade of AML cells","volume":"151","author":"Shao","year":"2020","journal-title":"Pharmacol. Res."},{"issue":"6_ement","key":"10.1016\/j.critrevonc.2026.105427_bib96","article-title":"Abstract 5709: PF-07104091, a first-in-class CDK2-selective inhibitor for the treatment of HR+\/HER2- breast cancer and CCNE1high ovarian cancer","volume":"Research 84","author":"Shen","year":"2024","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2026.105427_bib97","doi-asserted-by":"crossref","first-page":"S495","DOI":"10.1016\/j.annonc.2024.08.684","article-title":"617MO Safety and tolerability of INCB123667, a selective CDK2 inhibitor, in patients (pts) with advanced solid tumors: Axa0;phase I study","volume":"35","author":"Simonelli","year":"2024","journal-title":"Ann. Oncol."},{"issue":"914","key":"10.1016\/j.critrevonc.2026.105427_bib98","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.adv0415","article-title":"p16 expression confers sensitivity to CDK2 inhibitors in cyclin E1\u2013driven ovarian cancers","volume":"18","author":"Sine","year":"2025","journal-title":"Sci. Signal."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105427_bib99","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.molcel.2020.10.016","article-title":"Hyperactive CDK2 Activity in Basal-like Breast Cancer Imposes a Genome Integrity Liability that Can Be Exploited by Targeting DNA Polymerase \u03b5","volume":"80","author":"Sviderskiy","year":"2020","journal-title":"Mol. Cell."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105427_bib100","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.drudis.2019.12.001","article-title":"Targeting CDK2 in cancer: challenges and opportunities for therapy","volume":"25","author":"Tadesse","year":"2020","journal-title":"Drug. Discov. Today"},{"issue":"12_ement","key":"10.1016\/j.critrevonc.2026.105427_bib101","article-title":"Abstract P4-10-16: INX-315, an oral, potent and selective CDK2 inhibitor in patients with CDK4\/6 inhibitor resistant ER+\/HER2- breast cancer or CCNE1 amplified solid tumors: phase 1 monotherapy dose escalation","volume":"31","author":"Tan","year":"2025","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105427_bib102","doi-asserted-by":"crossref","first-page":"696","DOI":"10.18632\/oncotarget.2673","article-title":"Cyclin E1 and RTK\/RAS signaling drive CDK inhibitor resistance via activation of E2F and ETS","volume":"6","author":"Taylor-Harding","year":"2015","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105427_bib103","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1084\/jem.20172246","article-title":"CDK2 inhibitors as candidate therapeutics for cisplatin- and noise-induced hearing loss","volume":"215","author":"Teitz","year":"2018","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105427_bib104","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2174\/1570163812666150602144310","article-title":"Targeted Cancer Therapy: The Next Generation of Cancer Treatment","volume":"12","author":"Troy","year":"2015","journal-title":"Curr. Drug. Discov. Technol."},{"issue":"6340","key":"10.1016\/j.critrevonc.2026.105427_bib105","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/353174a0","article-title":"Isolation of the human cdk2 gene that encodes the cyclin A- and adenovirus E1A-associated p33 kinase","volume":"353","author":"Tsai","year":"1991","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105427_bib106","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/s41523-025-00767-2","article-title":"Baseline cell cycle and immune profiles indicate CDK4\/6 inhibitor response in metastatic HR\u2009+\u2009\/HER2- breast cancer","volume":"11","author":"Tzetzo","year":"2025","journal-title":"npj Breast Cancer"},{"key":"10.1016\/j.critrevonc.2026.105427_bib107","doi-asserted-by":"crossref","unstructured":"Volkart, P.A., Bitencourt-Ferreira, G., Souto, A.A., de Azevedo, W.F., 2018. Cyclin-Dependent Kinase 2 in Cellular Senescence and Cancer. A Structural and Functional Review. Curr Drug Targets.","DOI":"10.2174\/1389450120666181204165344"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105427_bib108","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/s41419-025-08156-0","article-title":"Targeting the ac4C \u2018Writer\u2019 NAT10 enhances pancreatic cancer immunotherapy via dual modulation of CD8+ T cells and tumor cells","volume":"16","author":"Wang","year":"2025","journal-title":"Cell. Death & Dis."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105427_bib109","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41589-021-00742-5","article-title":"Discovery of a first-in-class CDK2 selective degrader for AML differentiation therapy","volume":"17","author":"Wang","year":"2021","journal-title":"Nat. Chem. Biol."},{"issue":"16_","key":"10.1016\/j.critrevonc.2026.105427_bib110","article-title":"Phase 1\/2 study of ARTS-021, a potent, oral administrated, selective CDK2 inhibitor, in advanced or metastatic solid tumors","volume":"41","author":"Wang","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105427_bib111","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1016\/S0959-8049(22)01010-3","article-title":"Discovery of INCB123667, a potent and selective cyclin-dependent kinase 2 (CDK2) inhibitor for the treatment of cyclin E dysregulated cancers","volume":"174","author":"Wee","year":"2022","journal-title":"Eur. J. Cancer"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105427_bib112","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1093\/annonc\/mdz278","article-title":"Myelopreservation with the CDK4\/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib\/randomized phase II trial","volume":"30","author":"Weiss","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105427_bib113","doi-asserted-by":"crossref","unstructured":"Wilson, L.J., Linley, A., Hammond, D.E., Hood, F.E., Coulson, J.M., MacEwan, D.J., Ross, S.J., Slupsky, J.R., Smith, P.D., Eyers, P.A., Prior, I.A., 2017. New Perspectives, Opportunities, and Challenges in Exploring the Human Protein Kinome. Cancer Research.","DOI":"10.1158\/0008-5472.CAN-17-2291"},{"issue":"13","key":"10.1016\/j.critrevonc.2026.105427_bib114","doi-asserted-by":"crossref","first-page":"4265","DOI":"10.1074\/jbc.RA119.011571","article-title":"Doxorubicin induces cardiomyocyte apoptosis and atrophy through cyclin-dependent kinase 2\u2013mediated activation of forkhead box O1","volume":"295","author":"Xia","year":"2020","journal-title":"J. Biol. Chem."},{"issue":"51","key":"10.1016\/j.critrevonc.2026.105427_bib115","doi-asserted-by":"crossref","first-page":"19672","DOI":"10.1074\/jbc.RA118.004673","article-title":"Inhibition of cyclin-dependent kinase 2 protects against doxorubicin-induced cardiomyocyte apoptosis and cardiomyopathy","volume":"293","author":"Xia","year":"2018","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105427_bib116","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010301","article-title":"Acetyltransferase NAT10 inhibits T-cell immunity and promotes nasopharyngeal carcinoma progression through DDX5\/HMGB1 axis","volume":"13","author":"Xie","year":"2025","journal-title":"J. Immunother. Cancer"},{"issue":"25","key":"10.1016\/j.critrevonc.2026.105427_bib117","doi-asserted-by":"crossref","first-page":"20801","DOI":"10.18632\/oncotarget.4600","article-title":"Cyclin-dependent kinase 2 is an ideal target for ovary tumors with elevated cyclin E1 expression","volume":"6","author":"Yang","year":"2015","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105427_bib118","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41392-022-01168-8","article-title":"Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective","volume":"7","author":"Yang","year":"2022","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"16_","key":"10.1016\/j.critrevonc.2026.105427_bib119","article-title":"First-in-human phase 1\/2a study of a potent and novel CDK2-selective inhibitor PF-07104091 in patients (pts) with advanced solid tumors, enriched for CDK4\/6 inhibitor resistant HR+\/HER2- breast cancer","volume":"41","author":"Yap","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"24","key":"10.1016\/j.critrevonc.2026.105427_bib120","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1182\/blood-2017-10-813139","article-title":"Ubiquitin-dependent degradation of CDK2 drives the therapeutic differentiation of AML by targeting PRDX2","volume":"131","author":"Ying","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2026.105427_bib121","doi-asserted-by":"crossref","unstructured":"Yoon J. Choi, S.W., Victoria Brown, Neil Bifulco, Yeon S. Choi, Jian Guo, Megan Hatlen, 2021. Development of a selective CDK2-E inhibitor in CCNE-aberrant cancers. 81(13_Supplement):1279-1279. DOI:\u300810.1158\/1538-7445.AM2021-1279\u3009.","DOI":"10.1158\/1538-7445.AM2021-1279"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105427_bib122","doi-asserted-by":"crossref","first-page":"F52","DOI":"10.1152\/ajprenal.00119.2007","article-title":"Involvement of the CDK2-E2F1 pathway in cisplatin cytotoxicity in vitro and in vivo","volume":"293","author":"Yu","year":"2007","journal-title":"Am. J. Physiol. -Ren. Physiol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105427_bib123","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1158\/1541-7786.MCR-14-0163","article-title":"CDK2 Transcriptional Repression Is an Essential Effector in p53-Dependent Cellular Senescence\u2014Implications for Therapeutic Intervention","volume":"13","author":"Zalzali","year":"2015","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105427_bib124","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112503","article-title":"Clinical implications of chemotherapeutic agent organ toxicity on perioperative care","volume":"146","author":"Zeien","year":"2022","journal-title":"Biomed. & Pharmacother."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105427_bib125","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1080\/17460441.2024.2376655","article-title":"Inhibitors and PROTACs of CDK2: challenges and opportunities","volume":"19","author":"Zeng","year":"2024","journal-title":"Expert. Opin. Drug. Discov."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105427_bib126","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20190381","article-title":"Down-regulation of CCNE1 expression suppresses cell proliferation and sensitizes gastric carcinoma cells to Cisplatin","volume":"39","author":"Zhang","year":"2019","journal-title":"Biosci. Rep."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105427_bib127","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1038\/s41467-022-30264-0","article-title":"Inhibition of the CDK2 and Cyclin A complex leads to autophagic degradation of CDK2 in cancer cells","volume":"13","author":"Zhang","year":"2022","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105427_bib128","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s12885-019-5290-4","article-title":"CCNE1 amplification is associated with poor prognosis in patients with triple negative breast cancer","volume":"19","author":"Zhao","year":"2019","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105427_bib129","doi-asserted-by":"crossref","first-page":"6579","DOI":"10.1038\/s41467-022-34000-6","article-title":"MYC promotes immune-suppression in triple-negative breast cancer via inhibition of interferon signaling","volume":"13","author":"Zimmerli","year":"2022","journal-title":"Nat. Commun."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826003148?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826003148?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:38:50Z","timestamp":1793943530000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826003148"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":129,"alternative-id":["S1040842826003148"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105427","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The evolving landscape of CDK2 inhibition in cancer: Therapeutic potential, clinical progress, and future directions","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105427","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105427"}}